Pixalate's Q1 2024 Global Ad Fraud Benchmarks for Connected TV (CTV): $528 Million Spent on Ad Fraud & Invalid Traffic (IVT) Across CTV Platforms Including Roku, Amazon Fire TV, Apple TV, Samsung Smart TV
May 22, 2024 17:00 ET
|
Pixalate Inc.
LONDON, May 22, 2024 (GLOBE NEWSWIRE) -- Pixalate, the global market-leading ad fraud protection, privacy, and compliance analytics platform, today released the Q1 2024 Global Connected TV (CTV)...
Pixalate Releases Q1 2024 Global Ad Fraud (IVT) Benchmarks for Desktop & Mobile Web Traffic: 11% IVT Rate on Desktop Web Traffic; Firefox (24%) & Apple’s Safari (20%) Browsers Have Highest IVT Rate
May 22, 2024 16:37 ET
|
Pixalate Inc.
LONDON, May 22, 2024 (GLOBE NEWSWIRE) -- Pixalate, the global market-leading ad fraud protection, privacy, and compliance analytics platform, today released the Q1 2024 Global Desktop & Mobile...
[Latest] Global Well Testing Services Market Size/Share Worth USD 13.6 Billion by 2033 at a 6.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 21, 2024 14:00 ET
|
Custom Market Insights
Austin, TX, USA, May 21, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Well Testing Services Market Size, Trends and Insights By Well Type (Horizontal...
Blue Mountain Appoints Chief Growth Officer to Spearhead Global Expansion and Strategic Partnerships in Life Sciences Sector
May 21, 2024 09:00 ET
|
Blue Mountain
Blue Mountain names Keith Pensabene as Chief Growth Officer, leading global growth and strategic partnerships in the life sciences sector.
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
May 21, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
Amplexd Therapeutics, Innovating to Revolutionize the Future of Non-Invasive HPV-induced Cervical Intraepithelial Neoplasia (CIN) Treatments for the Prevention of Cervical Cancer: Developed by Women for Women
May 21, 2024 08:00 ET
|
Amplexd Therapeutics Inc.
GAITHERSBURG, MD, May 21, 2024 (GLOBE NEWSWIRE) -- Amplexd Therapeutics, Inc. (“Amplexd” or the “Company”), a clinical stage patient-scientist-led biotech company specializing in accessible...
Pixalate Releases Q1 2024 Global Connected TV (CTV) Seller Trust Indexes: Index Exchange, TripleLift, FreeWheel Lead in SSP Quality Rankings for Open Programmatic Ad Supply on Amazon Fire TV
May 20, 2024 15:15 ET
|
Pixalate Inc.
LONDON, May 20, 2024 (GLOBE NEWSWIRE) -- Pixalate, the global market-leading ad fraud protection, privacy, and compliance analytics platform, today released the Q1 2024 Connected TV (CTV) Seller...
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
May 20, 2024 07:00 ET
|
Ocugen
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes
May 20, 2024 07:00 ET
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or “the Company”) AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2...
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
May 20, 2024 06:00 ET
|
Fractyl Health, Inc.
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024